On February 23, 2021 Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, reported that its Board of Directors approved a 7% increase in the Company’s quarterly dividend to $0.24 per share from $0.225 per share (Press release, Perrigo Company, FEB 23, 2021, View Source [SID1234575458]). This dividend increase marks the 18th consecutive year Perrigo has increased its dividend.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The cash dividend is payable on March 30, 2021 to shareholders of record on March 12, 2021.

On February 23, 2021 Propella Therapeutics Inc. (Propella), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), part of the National Institutes of Health, reported that have entered into a Cooperative Research and Development Agreement (CRADA) (Press release, Propella Therapeutics, FEB 23, 2021, View Source [SID1234575457]). Under this new partnership, Propella and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Propella holds U.S. Patent 10,792,292, which protects multiple new long-acting, injectable, prodrugs of abiraterone, and includes composition of matter, method of manufacturing, and method of treatment claims. The acetate prodrug of abiraterone, which is given by mouth daily, is a current standard of care for advanced prostate cancer. Abiraterone acetate produces varying blood concentrations of abiraterone metabolites, including high levels that may produce side effects and low levels that may not be effective. Preclinical data indicate that a single injection of Propella’s novel intramuscular (IM) formulation of abiraterone decanoate can deliver more precise drug levels that may prove effective for up to 3 months, potentially providing patients with both greater drug effectiveness and assurance of increased safety.

Propella presented select preclinical findings on Feb. 11, 2021, at the (virtual) annual meeting of The American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), Genitourinary Division (GU ASCO (Free ASCO Whitepaper)) that confirmed large and continuous 3-month reductions in testosterone following a single IM injection. The presentation may now be viewed on the Propella website at: View Source

"We’re gratified to have had the opportunity to present compelling preclinical program results at the prestigious GU ASCO (Free ASCO Whitepaper) conference, and to work collaboratively with the scientists at the National Cancer Institute," said Propella President and CEO William Moore, PhD. "The upcoming clinical trial has the potential for abiraterone decanoate to improve the standard of care for patients with advanced prostate cancer."

Under the CRADA, Propella will file and hold the Investigational New Drug application (IND) while NCI will provide clinical research and development expertise along with pharmacokinetic and clinical pharmacology insights and analyses.

According to Dr. William Douglas Figg, Sr., Senior Investigator and Head of the Clinical Pharmacology Program at the NCI, "Propella’s intramuscular formulation of abiraterone, abiraterone decanoate, is an interesting new agent and we look forward to investigating its potential as a therapy choice for men with prostate cancer."

On February 23, 2021 Genmab A/S (Nasdaq: GMAB) reported that it is initiating a share buy-back program to mitigate dilution from warrant exercises and honor our commitments under our Restricted Stock Unit program (Press release, Genmab, FEB 23, 2021, View Source [SID1234575456]). The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbour Regulation."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Purpose
The purpose of the share buy-back program is to mitigate dilution caused by warrant exercises and to honor our commitments under our Restricted Stock Unit program.

Time frame
The share buy-back program will start on February 24, 2021 and will be completed no later than June 30, 2021 (unless Genmab terminates or suspends the program).

Terms
Genmab has appointed Danske Bank as lead manager for the share buy-back program. Danske Bank will make its own trading decisions and act independently of and without influence or involvement from Genmab. Under this share buy-back program Genmab may repurchase up to 200,000 shares.

Shares acquired under the program cannot be purchased at a price exceeding the higher of (i) the price of the latest independent transaction on Nasdaq Copenhagen and (ii) the price of the highest independent bid on Nasdaq Copenhagen at the time of the transaction. The total number of shares that may be purchased on a single trading day may not exceed 25% of the average daily trading volume over the preceding 20 trading days on Nasdaq Copenhagen.

As of February 23, 2021, Genmab holds 102,977 treasury shares equal to 0.16% of the share capital.

Genmab is entitled to suspend or stop the program at any time subject to announcement to Nasdaq Copenhagen.

Upon initiation of the program, Genmab will issue a weekly announcement in respect of transactions made under the program.

On February 23, 2021 Genmab A/S (Nasdaq: GMAB) reported the publication of its Annual Report for 2020. Below is a summary of business progress in 2020, financial performance for the year and the financial outlook for 2021 (Press release, Genmab, FEB 23, 2021, View Source [SID1234575455]). The full report is attached as a PDF file and can be found on the investor section of the company’s website, www.genmab.com/investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call
Genmab will hold a conference call in English to discuss the full year results for 2020 today, February 23, 2021 at 6:00 pm CET, 5:00 pm GMT or noon EST. To join the call dial +1 631 913 1422 (U.S. participants) or +44 3333 000804 (international participants) and provide conference code 82034909.

A live and archived webcast of the call and relevant slides will be available at www.genmab.com/investors.

On February 23, 2021 Microbiologist Henry Skinner, formerly of Novartis and Tekla Capital, reported it has been announced as the first CEO of the AMR Action Fund, a joint venture aimed at strengthening and accelerating clinical research of new, innovative antibiotics to address the rising issue of antimicrobial resistance (AMR) (Press release, EVERSANA, FEB 23, 2021, View Source [SID1234575454]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through the joint efforts of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Investment Bank, and Wellcome Trust, the AMR Action Fund first launched in July 2020 with $1 billion in funding with the goal of bringing four new antibiotics to patients by 2030.

Skinner stated, "I am honored to join the AMR Action Fund and its incredibly important mission. Having worked on this issue from many angles throughout my career, I know how badly novel antibiotics are needed, and I also know how many obstacles currently prevent them from being developed and reaching patients. I am proud and excited to lead the AMR Action Fund in its efforts to tackle the global challenge of AMR. Thank you to everyone involved in developing this critical and groundbreaking initiative, and in particular to the interim CEO of the AMR Action Fund, Martin Bott, for getting us to this point."

The Fund is poised to "take its first steps" in investing in biotech companies focused on developing new antibodies.

At the same time as Skinner was confirmed as CEO, it was announced that the fund had received an additional $140 million in funding from Boehringer Ingelheim Foundation, the European Investment Bank, and Wellcome Trust.

Christoph Boehringer, Chairman of the Boehringer Ingelheim Foundation, commented, "We need innovative solutions to avert the looming health crisis posed by AMR, which threatens to make even common medical procedures potentially deadly. The Boehringer Ingelheim Foundation is committed to fighting the greatest global health threats of our time and we are proud to join this broad alliance of charitable organizations, development banks, and biopharmaceutical companies. We are confident the AMR Action Fund will enable researchers and scientists to bring innovative antibiotics to patients suffering from severe bacterial infections."

The Fund noted that, while additional funding serves as a short-term solution to AMR, longer term policies are necessary to boost the pipeline of new antibiotics.